Page last updated: 2024-08-21

azomycin and Neutropenia

azomycin has been researched along with Neutropenia in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Barreira, F; Bilbe, G; Blum, B; Gascón, J; Ortiz, L; Palacios, A; Pinazo, MJ; Pinto, J; Ribeiro, I; Rojas, G; Schijman, AG; Strub-Wourgaft, N; Torrico, F; Vaillant, M1
Andreeff, M; Benito, J; Borthakur, G; Bueso-Ramos, C; Cortes, J; Coveler, A; Daver, N; Estey, EH; Faderl, S; Feliu, J; Gu, Y; Gutheil, JC; Jabbour, E; Kadia, T; Kantarjian, H; Konoplev, S; Konopleva, M; Kornblau, S; Lu, H; Melink, TJ; Nguyen, HQ; Pemmaraju, N; Ravandi, F; Thall, PF; Thomas, D; Wei, C; Wilson, WR; Yi, CA1
Adkins, D; Butrynski, JE; Chawla, SP; Cranmer, LD; Ganjoo, KN; Kroll, S; Langmuir, VK; Lorente, G; Okuno, SH; Rushing, D1

Trials

3 trial(s) available for azomycin and Neutropenia

ArticleYear
A Phase 2, Randomized, Multicenter, Placebo-Controlled, Proof-of-Concept Trial of Oral Fexinidazole in Adults With Chronic Indeterminate Chagas Disease.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 02-08, Volume: 76, Issue:3

    Topics: Adult; Chagas Disease; Double-Blind Method; Humans; Neutropenia; Nitroimidazoles; Treatment Outcome

2023
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.
    Haematologica, 2015, Volume: 100, Issue:7

    Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Biomarkers; Bone Marrow; Carbonic Anhydrase IX; Carbonic Anhydrases; Enterocolitis; Female; Gene Expression; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Nitroimidazoles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prodrugs; Recurrence; Remission Induction; Thrombocytopenia

2015
A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.
    Oncology, 2011, Volume: 80, Issue:1-2

    Topics: Abscess; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cellulitis; Disease-Free Survival; Doxorubicin; Drug Eruptions; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphopenia; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neutropenia; Nitroimidazoles; Phosphoramide Mustards; Sarcoma; Stomatitis; Treatment Outcome; Young Adult

2011